SLC7A14

Across TCGA pan-cancer cohorts, SLC7A14 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC7A14 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SLC7A14 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC7A14 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SARC show a favorable association.

LIHC, UCEC, and PRAD are the cancer types where SLC7A14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.128	0.783	.001	36	view →
UCEC	DFS	Median	All	0.977	0.825	.006	34	view →
PRAD	DFS	Median	All	0.157	0.888	<.001	12	view →
MESO	DFS	Median	All	0.099	0.392	.030	9	view →
LUAD	OS	Median	II,III,IV	0.164	0.681	<.001	6	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	3	view →
SARC	DFS	Median	All	1.000	0.326	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC7A14–LIHC (OS)

Open the LIHC breakdown →